Benefits and costs of immunizing children against influenza at school: an economic analysis based on a large-cluster controlled clinical trial.

Current influenza vaccination recommendations focus on immunizing high-risk people; however, influenza mortality and morbidity remain elevated. U.S. policymakers are considering expansion of flu vaccination recommendations to include school-age children (ages 5-18). Children are at risk for flu and propagate epidemic spread. Immunizing children at school offers an efficient approach to covering this population. This study examines the cost consequences of a large multistate, school-based influenza immunization program. The results show that immunization reduces disease among children and adults and is cost-saving to society. An epidemiologically based influenza immunization policy might be an important supplement to the existing risk-based policy.

[1]  L. Magder,et al.  A Pilot Study of the Effectiveness of a School-Based Influenza Vaccination Program , 2005, Pediatrics.

[2]  D. Fleming,et al.  Safety, Efficacy, and Effectiveness of Cold-Adapted Influenza Vaccine-Trivalent Against Community-Acquired, Culture-Confirmed Influenza in Young Children Attending Day Care , 2006, Pediatrics.

[3]  L. Simonsen,et al.  The Japanese experience with vaccinating schoolchildren against influenza. , 2001, The New England journal of medicine.

[4]  H. Lawson,et al.  Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2007, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[5]  L. Magder,et al.  Effectiveness of school-based influenza vaccination. , 2006, The New England journal of medicine.

[6]  D. Swerdlow,et al.  Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain spotted fever, ehrlichioses, and anaplasmosis--United States: a practical guide for physicians and other health-care and public health professionals. , 2006, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[7]  M. Meltzer,et al.  An economic analysis of annual influenza vaccination of children. , 2005, Vaccine.

[8]  T. Lieu,et al.  Health Benefits, Risks, and Cost-Effectiveness of Influenza Vaccination of Children , 2006, Emerging infectious diseases.

[9]  Pedro A Piedra,et al.  Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children. , 2005, Vaccine.

[10]  A. Detsky,et al.  Costs and cost-effectiveness of a universal, school-based hepatitis B vaccination program. , 1998, American journal of public health.

[11]  Lihan K. Yan,et al.  Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. , 2000, The Journal of pediatrics.

[12]  M. Meltzer,et al.  Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial. , 2000, JAMA.

[13]  N. Cox,et al.  Prevention and Control of Influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2006, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[14]  R. Walker,et al.  Live attenuated versus inactivated influenza vaccine in infants and young children. , 2007, The New England journal of medicine.